AIM ImmunoTech CEO buys 5,900 shares at $0.219
AIM ImmunoTech’s CEO and President increased his direct AIM shareholdings through an open-market style purchase.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
AIM ImmunoTech Inc. (AIM) reported that CEO and President Thomas K. Equels purchased 5,900 shares of its Common Stock on September 14, 2026, in a purchase characterized as an open market or private transaction at $0.219 per share. Following this transaction, he holds 69,822 shares with direct ownership, and no Rule 10b5-1 trading plan is reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 5,900 | $0.219 | $1K |
Key Figures
Key Terms
purchase in open market or private transaction financial
direct ownership financial
Rule 10b5-1 trading plan regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did AIM ImmunoTech Inc. (AIM) disclose in this Form 4?
Was the AIM (AIM) insider trade made under a Rule 10b5-1 trading plan?
Does the Form 4 for AIM (AIM) report any stock sales by the CEO?
AI-generated analysis. How Rhea-AI works. Not financial advice.